Our reports and articles feature research and analysis on topics that matter most in digital health today.
As technology continues to influence healthcare, our insights are designed to help you understand what comes next and make better decisions in digital health.
By embracing digital measures, pharma can accelerate drug development, improve patient outcomes. Pharma can and will continue to compete on assets, but should not compete on (digital) endpoints. We require industry collaborations in order to usher in a new era of medicine.
Digital measures have the potential to revolutionise drug development. However, pharma has been slow to fully utilise these measures due to their high costs and lack of standardised applications across therapeutic areas.
This report presents an expert-led analysis of the state of digital measures in drug development. More specifically, the report delves into:
Download the report to learn what our HealthXL community experts believe is in store for the future of digital measures in drug development and how best to prepare for it.
Explore our latest thinking, expert analysis and community insights on what matters most in digital health.
2024 has been off to a great start at HealthXL, with topics ranging from How to Scale Partnerships Between Lifesciences and Digital Health Companies? to Real World Data in Clinical Trials: Benefits and Best Practices.Read more
AI holds the promise of revolutionising clinical trials, specifically by automating and optimising critical processes. The technology has the capability to significantly boost productivity, cut costs, and accelerate the overall timeline of clinical trials.Read more
Many of you may still be relishing in the holiday bliss, but for HealthXL, the new year is already in full swing. Before we properly close the door on last year, I wanted to take a minute (or so …) to reflect on the tumultuous year that has been.Read more